Argininosuccinate lyase interacts with cyclin A2 in cytoplasm and modulates growth of liver tumor cells

  • Authors:
    • Yu-Hsuan Hung
    • Hau-Lun Huang
    • Wei-Ching Chen
    • Meng-Chi Yen
    • Chien-Yu Cho
    • Tzu-Yang Weng
    • Chih-Yang Wang
    • Yi-Ling Chen
    • Li-Tzong Chen
    • Ming-Derg Lai
  • View Affiliations

  • Published online on: December 23, 2016     https://doi.org/10.3892/or.2016.5334
  • Pages: 969-978
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Arginine is a critical amino acid in specific cancer types including hepatocellular carcinoma (HCC) and melanoma. Novel molecular mechanisms and therapeutic targets in arginine metabolism-mediated cancer formation await further identification. Our laboratory has previously demonstrated that arginine metabolic enzyme argininosuccinate lyase (ASL) promoted HCC formation in part via maintenance of cyclin A2 protein expression and arginine production for channeling to nitric oxide synthase. In this study, we investigated the mechanism by which ASL regulates cyclin A2 expression. We found that ASL interacted with cyclin A2 in HCC cells and the localization of their interaction was in the cytoplasm. Mutation of essential residues for enzymatic activity of ASL did not affect the binding of ASL to cyclin A2. Moreover, the mutant ASL retained the ability to restore the decreased tumorigenicity caused by ASL shRNA. Furthermore, overexpression of ASL conferred resistance to arginine deprivation therapy. Finally, the important pathways and potential therapeutic targets in ASL-regulated HCC were identified by bioinformatics analyses with Metacore database and Connectivity Map database. Our analyses suggested that bisoprolol, celecoxib, and ipratropium bromide, are potential therapeutics for ASL-regulated HCC formation. Thus, ASL interacts with cyclin A2 in cytoplasm, and may promote HCC formation through this non-enzymatic function. Overexpression of ASL may be a contributing factor in drug resistance for arginine deprivation therapy.
View Figures
View References

Related Articles

Journal Cover

February-2017
Volume 37 Issue 2

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Hung Y, Huang H, Chen W, Yen M, Cho C, Weng T, Wang C, Chen Y, Chen L, Lai M, Lai M, et al: Argininosuccinate lyase interacts with cyclin A2 in cytoplasm and modulates growth of liver tumor cells. Oncol Rep 37: 969-978, 2017
APA
Hung, Y., Huang, H., Chen, W., Yen, M., Cho, C., Weng, T. ... Lai, M. (2017). Argininosuccinate lyase interacts with cyclin A2 in cytoplasm and modulates growth of liver tumor cells. Oncology Reports, 37, 969-978. https://doi.org/10.3892/or.2016.5334
MLA
Hung, Y., Huang, H., Chen, W., Yen, M., Cho, C., Weng, T., Wang, C., Chen, Y., Chen, L., Lai, M."Argininosuccinate lyase interacts with cyclin A2 in cytoplasm and modulates growth of liver tumor cells". Oncology Reports 37.2 (2017): 969-978.
Chicago
Hung, Y., Huang, H., Chen, W., Yen, M., Cho, C., Weng, T., Wang, C., Chen, Y., Chen, L., Lai, M."Argininosuccinate lyase interacts with cyclin A2 in cytoplasm and modulates growth of liver tumor cells". Oncology Reports 37, no. 2 (2017): 969-978. https://doi.org/10.3892/or.2016.5334